|4Jun 20, 6:45 PM ET

Beck John W 4

4 · Ardea Biosciences, Inc./DE · Filed Jun 20, 2012

Insider Transaction Report

Form 4
Period: 2012-06-19
Beck John W
SVP, Finance & Operations, CFO
Transactions
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2012-06-19$8.34/sh4,503$37,5550 total
    Exercise: $23.66Exp: 2020-12-13Common Stock (4,503 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2012-06-19$17.74/sh155,952$2,766,5880 total
    Exercise: $14.26Exp: 2018-05-26Common Stock (155,952 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2012-06-19$26.15/sh6,250$163,4380 total
    Exercise: $5.85Exp: 2017-06-14Common Stock (6,250 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2012-06-19$16.31/sh12,500$203,8750 total
    Exercise: $15.69Exp: 2018-01-01Common Stock (12,500 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2012-06-19$21.32/sh44,000$938,0800 total
    Exercise: $10.68Exp: 2018-12-18Common Stock (44,000 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2012-06-19$8.34/sh15,497$129,2450 total
    Exercise: $23.66Exp: 2020-12-13Common Stock (15,497 underlying)
  • Disposition to Issuer

    Common Stock

    2012-06-19$32.00/sh4,409$141,0880 total
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2012-06-19$16.31/sh12,500$203,8750 total
    Exercise: $15.69Exp: 2018-01-01Common Stock (12,500 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2012-06-19$17.05/sh6,250$106,5630 total
    Exercise: $14.95Exp: 2019-12-15Common Stock (6,250 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2012-06-19$17.05/sh18,750$319,6880 total
    Exercise: $14.95Exp: 2019-12-15Common Stock (18,750 underlying)
Footnotes (1)
  • [F1]This option was canceled pursuant to the Agreement and Plan of Merger, dated as of April 21, 2012, by and among Ardea Biosciences, Inc. ("Ardea"), Zeneca Inc. and QAM Corp. (the "Merger Agreement"), in exchange for a payment in cash, without interest and less the amount of any required tax withholding, equal to the product of: (i) the excess of $32.00 (the per share merger consideration pursuant to the Merger Agreement) over the exercise price of the option; and (ii) the number of shares of Ardea common stock underlying the option.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION